- Home
- ICCC vs AKTX Comparison
ICCC vs AKTX Comparison
Compare ICCC & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- AKTX
- Stock Information
- Founded
- ICCC 1982
- AKTX N/A
- Country
- ICCC United States
- AKTX United States
- Employees
- ICCC N/A
- AKTX N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- ICCC Health Care
- AKTX Health Care
- Exchange
- ICCC Nasdaq
- AKTX Nasdaq
- Market Cap
- ICCC 28.0M
- AKTX 29.5M
- IPO Year
- ICCC 1987
- AKTX N/A
- Fundamental
- Price
- ICCC $4.71
- AKTX $0.95
- Analyst Decision
- ICCC
- AKTX
- Analyst Count
- ICCC 0
- AKTX 0
- Target Price
- ICCC N/A
- AKTX N/A
- AVG Volume (30 Days)
- ICCC 22.4K
- AKTX 64.1K
- Earning Date
- ICCC 11-13-2024
- AKTX 02-15-2025
- Dividend Yield
- ICCC N/A
- AKTX N/A
- EPS Growth
- ICCC N/A
- AKTX N/A
- EPS
- ICCC N/A
- AKTX N/A
- Revenue
- ICCC $23,838,001.00
- AKTX N/A
- Revenue This Year
- ICCC N/A
- AKTX N/A
- Revenue Next Year
- ICCC N/A
- AKTX N/A
- P/E Ratio
- ICCC N/A
- AKTX N/A
- Revenue Growth
- ICCC 46.37
- AKTX N/A
- 52 Week Low
- ICCC $3.34
- AKTX $0.90
- 52 Week High
- ICCC $5.82
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- ICCC 56.95
- AKTX 30.69
- Support Level
- ICCC $4.38
- AKTX $0.95
- Resistance Level
- ICCC $5.23
- AKTX $1.04
- Average True Range (ATR)
- ICCC 0.47
- AKTX 0.13
- MACD
- ICCC -0.04
- AKTX 0.03
- Stochastic Oscillator
- ICCC 22.92
- AKTX 4.26
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).